-transparent.png){kind=logo}
The effect of proglumide on cholecystokinin (CCK)-stimulated amylase release was studied in vitro and in vivo in dispersed acini from mouse pancreas. In an in vitro study, proglumide at concentrations between 0.3-10 mM inhibited CCK-stimulated amylase release dose-dependently, while proglumide did not influence the basal amylase release at concentrations between 0-3 mM. Dose-response curves to CCK for amylase release shifted to the right with increase in proglumide concentration. This inhibition by proglumide was reversible. In addition, the effect of proglumide was selective for CCK and its related peptide, and this drug did not inhibit other secretagogues such as carbachol or gastrin releasing peptide in mouse acini. In contrast to its inhibitory effect in vitro, in vivo administration of proglumide (500 mg/kg/day, i.p., for 5 days) to mice did not cause the rightward shift of the dose-response curve to CCK for amylase release from dispersed acini.
Y Iwamoto, and
R Nakamura, and
Y Akanuma
October 1987,
Biochimica et biophysica acta,
Y Iwamoto, and
R Nakamura, and
Y Akanuma
May 1992,
The Journal of laboratory and clinical medicine,
Y Iwamoto, and
R Nakamura, and
Y Akanuma
July 2001,
Pancreas,
Y Iwamoto, and
R Nakamura, and
Y Akanuma
January 1987,
Pancreas,
Y Iwamoto, and
R Nakamura, and
Y Akanuma
November 1997,
Gastroenterology,
Y Iwamoto, and
R Nakamura, and
Y Akanuma
September 1990,
Surgery,
Y Iwamoto, and
R Nakamura, and
Y Akanuma
January 1987,
Pancreas,
Y Iwamoto, and
R Nakamura, and
Y Akanuma
January 1988,
Pancreas,
Y Iwamoto, and
R Nakamura, and
Y Akanuma
November 1995,
Pancreas,
Y Iwamoto, and
R Nakamura, and
Y Akanuma
October 1980,
The American journal of physiology,
